Premium Nahrungsergänzungsmittel | artgerecht

Lactate Dehydrogenase Therapy - LDH Explained

Lactate dehydrogenase therapy refers to therapeutic approaches targeting the enzyme lactate dehydrogenase (LDH) to treat metabolic disorders and cancer.

Regular tips about health Regular tips about health

Things worth knowing about "Lactate dehydrogenase therapy"

Lactate dehydrogenase therapy refers to therapeutic approaches targeting the enzyme lactate dehydrogenase (LDH) to treat metabolic disorders and cancer.

What is Lactate Dehydrogenase Therapy?

Lactate dehydrogenase therapy (LDH therapy) is a field of medical research and clinical application focused on the targeted modulation of the enzyme lactate dehydrogenase (LDH). LDH is a key enzyme in cellular energy metabolism, catalyzing the interconversion of pyruvate and lactate. Therapeutic strategies targeting LDH are gaining increasing importance, particularly in oncology and metabolic disease management.

Biological Function of Lactate Dehydrogenase

LDH is a ubiquitous enzyme found in virtually all body cells. It plays a central role in anaerobic glucose metabolism (glycolysis) and is responsible for maintaining energy supply under low-oxygen conditions. The enzyme exists in five isoforms (LDH-1 to LDH-5), predominating in different tissues:

LDH-1 and LDH-2: Mainly in cardiac muscle and red blood cells
LDH-3: Primarily in lung and lymphoid tissue
LDH-4 and LDH-5: Primarily in liver and skeletal muscle

Elevated LDH levels in the blood may indicate tissue damage, myocardial infarction, liver disease, or malignant conditions.

Therapeutic Approach: Why LDH as a Target?

Tumor cells preferentially use anaerobic metabolic pathways – a phenomenon known as the Warburg effect – and are therefore particularly dependent on LDH activity. Inhibiting LDH, especially the isoform LDH-A (LDHA), represents a promising approach in cancer therapy. By blocking this enzyme, the energy supply to tumor cells is intended to be disrupted and their growth inhibited.

Mechanism of Action of LDH Inhibition

LDH inhibitors intervene specifically in the metabolism of tumor cells:

Inhibition of the conversion of pyruvate to lactate in tumor cells
Accumulation of pyruvate, which is redirected into mitochondrial oxidative metabolism
Increased oxidative stress in tumor cells
Induction of apoptosis (programmed cell death) in malignant cells
Reduction of lactate secretion, which contributes to immunosuppression in the tumor microenvironment

Clinical Areas of Application

Oncology

In cancer medicine, LDH therapy is being investigated as a potential complementary treatment strategy. Elevated LDH blood levels are considered a negative prognostic marker in various cancers, including malignant melanoma, lymphomas, and solid tumors. Substances such as gossypol, oxamate, and newer synthetic LDHA inhibitors are currently in preclinical and early clinical trials.

Metabolic Disorders

In certain metabolic conditions such as lactic acidosis syndrome, modulation of LDH activity may be therapeutically relevant. The goal here is to normalize the lactate-pyruvate balance in the body.

Musculoskeletal Conditions

Since LDH-5 is present in skeletal muscle, LDH activity is being studied as a diagnostic and therapeutically relevant biomarker in conditions involving increased muscle breakdown.

LDH as a Diagnostic Marker

In addition to its therapeutic role, LDH is an important laboratory diagnostic value. Elevated LDH levels may indicate the following conditions:

Myocardial infarction (heart attack)
Liver diseases (e.g., hepatitis, liver cirrhosis)
Hemolytic anemia
Malignant diseases (e.g., lymphomas, melanoma)
Kidney disorders
Pulmonary embolism

The determination of LDH isoforms can help to more precisely identify the origin of cell damage.

Current State of Research

The development of specific LDH inhibitors is a global focus of pharmaceutical research. Numerous studies confirm the importance of LDHA as an oncological target structure. Current research is investigating the combination of LDH inhibitors with conventional chemotherapy or immunotherapy to achieve synergistic effects and overcome tumor cell resistance. Phase I and Phase II clinical trials are underway, but broad clinical approval of specific LDH inhibitors is still pending.

Safety and Side Effects

Since LDH is present in virtually all body cells, systemic inhibition of the enzyme carries potential risks for healthy tissue. Discussed adverse effects include:

Impairment of energy supply in muscle cells
Potential effects on cardiac muscle cells
Alterations in the lactate-pyruvate balance throughout the body

The targeted development of tumor-specific inhibitors that preferentially inhibit LDHA is intended to minimize these risks.

References

Doherty, J.R. & Cleveland, J.L. (2013). Targeting lactate metabolism for cancer therapeutics. Journal of Clinical Investigation, 123(9), 3685–3692. DOI: 10.1172/JCI69741
Warburg, O. (1956). On the origin of cancer cells. Science, 123(3191), 309–314.
Granchi, C. et al. (2014). Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials. Current Medicinal Chemistry, 21(35), 3972–3987.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.

Most read entries

3 Posts in this encyclopedia category